U.S. markets open in 5 hours 41 minutes
  • S&P Futures

    4,126.25
    +19.25 (+0.47%)
     
  • Dow Futures

    34,069.00
    +131.00 (+0.39%)
     
  • Nasdaq Futures

    13,184.00
    +83.75 (+0.64%)
     
  • Russell 2000 Futures

    2,180.60
    +12.00 (+0.55%)
     
  • Crude Oil

    63.89
    +0.07 (+0.11%)
     
  • Gold

    1,832.60
    +8.60 (+0.47%)
     
  • Silver

    27.09
    +0.05 (+0.19%)
     
  • EUR/USD

    1.2120
    +0.0035 (+0.29%)
     
  • 10-Yr Bond

    1.6680
    0.0000 (0.00%)
     
  • Vix

    22.02
    -5.57 (-20.19%)
     
  • GBP/USD

    1.4067
    +0.0015 (+0.11%)
     
  • USD/JPY

    109.4110
    -0.0230 (-0.02%)
     
  • BTC-USD

    49,991.55
    -788.08 (-1.55%)
     
  • CMC Crypto 200

    1,379.62
    -8.29 (-0.60%)
     
  • FTSE 100

    7,001.37
    +38.04 (+0.55%)
     
  • Nikkei 225

    28,084.47
    +636.46 (+2.32%)
     

Looking Into WAVE Life Sciences's Return On Capital Employed

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

WAVE Life Sciences (NASDAQ:WVE) reported Q4 sales of $9.44 million. Earnings fell to a loss of $30.31 million, resulting in a 11.92% decrease from last quarter. In Q3, WAVE Life Sciences brought in $3.45 million in sales but lost $34.41 million in earnings.

Why ROCE Is Significant

Changes in earnings and sales indicate shifts in WAVE Life Sciences's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q4, WAVE Life Sciences posted an ROCE of -0.33%.

It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.

View more earnings on WVE

ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows WAVE Life Sciences is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.

In WAVE Life Sciences's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.

Q4 Earnings Insight

WAVE Life Sciences reported Q4 earnings per share at $-0.59/share, which beat analyst predictions of $-0.61/share.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.